Results · Apr-Jun 2026 · filed 10 Aug 2026
IOL Chemicals & Pharmaceuticals Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 37% to ₹756 crore from ₹552 crore in Apr-Jun 2025.
Operating profit grew 67% to ₹103 crore, an operating margin of 13.7% (up 2.4 points from a year ago).
Net profit grew 90% to ₹64.4 crore from ₹33.9 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +22%, net profit +21%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 756.3 | 551.7 | +37% |
| Operating profit (EBITDA) | 103.5 | 62.1 | +67% |
| Operating margin | 13.7% | 11.3% | +2.4 pts |
| Net profit | 64.4 | 33.9 | +90% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
IOL reported Apr–Jun 2026 revenue of ₹756 crore (37% growth from a year earlier) & PAT of ₹64.5 crore (90% growth). Non-ibuprofen APIs reached 43% of pharma revenue & grew 67% from a year earlier. Management guides FY27 revenue growth of 15-20% & EBITDA margin of 14-15%.
The last 7 quarters
Filings that week
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 11 Aug 2026Communication To The Shareholders Regarding AGM Notice And Annual Report For The Financial Year 2025-26
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 10 Aug 2026Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2026
- 10 Aug 2026Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2026
- 8 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.